Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Nab-paclitaxel in 2nd-line Gastric Cancer
NCT04294784Phase 2Terminated
- Sponsor
- Huazhong University of Science and Technology
- Start
- Apr 2020
- Primary completion
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in gastric adenocarcinoma, esophagogastric junction adenocarcinoma (GEJA), sponsored by Huazhong University of Science and Technology. Started Apr 2020; status: terminated.
02
Drugs
camrelizumab
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT04294784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04294784.